Clear Search sequence regions


  • adriamycin (1)
  • adult (1)
  • bleomycin (3)
  • cases (1)
  • CD15 (1)
  • CD20 (1)
  • CD30 (1)
  • city (1)
  • dehydrogenases (2)
  • doxorubicin (2)
  • female (1)
  • hemoglobins (2)
  • hodgkin disease (1)
  • hodgkin lymphoma (6)
  • humans (1)
  • iraq (4)
  • low hemoglobin (1)
  • lymphocyte (1)
  • patients (6)
  • protocols (1)
  • Sizes of these terms reflect their relevance to your search.

    Hodgkin lymphoma (HL) has unique epidemiological features with diverse pathologies and exhibits considerable clinicopathological variations in different parts of the world. In this study, we aimed to assess the clinicopathological features, immunohistochemistry, and outcomes of HL patients treated in Erbil, northern Iraq. This was a retrospective study conducted in Nanakaly Hospital for Blood Diseases and Oncology in Erbil, Iraq. A total of 125 patients diagnosed between January 2012 and December 2016 were assessed for their clinical characteristics, histopathology, immunophenotype, and outcome. The median age was 28 years (range: 18-71 years); 55% were male and 41% had Stage II HL. The most common histological type was nodular sclerosis (51.2%) followed by mixed cellularity (43.2%). CD30 was positive in nearly all cases of classical HL. CD15 and CD20 were positive in 98.7% and 75% of patients with the nodular lymphocyte predominant subtype, respectively. Most of the patients received adriamycin, bleomycin, vinblastine, and dacarbazine chemotherapy, and the 5-year overall survival in our study is 70%. Advanced stage (IV), high lactate dehydrogenase levels, low hemoglobin, and splenomegaly are significant predictors of poor survival. Our patients exhibited outcomes that were lower than those reported in developed countries. Copyright © 2022 Elsevier Inc. All rights reserved.

    Citation

    Lilan Mohammedzaki, Kawa Hasan. HL-048 Clinicopathological, Immunohistochemical Characteristics, and Outcomes of Hodgkin Lymphoma Patients in Erbil City, Iraq. Clinical lymphoma, myeloma & leukemia. 2022 Oct;22 Suppl 2:S343-S344

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 36164020

    View Full Text